In the News

Le Dauphine Libere
National Institute for Health Research
Lokalzeit aus Bonn (March 26, 2015)
9 News (March 9, 2015)
WDRB (March 1, 2015)
The Courier-Journal (Feb 25, 2015)
Clinica (Feb 2, 2015)
U of L Today (Jan 28, 2015)

Press Releases

First Prospective, Randomized Controlled Study Using the Chartis System to Select Patients Confirms Clinical Superiority of Zephyr® EBV Therapy over Medical Management in Treating Emphysema

Redwood City, Calif. – December 9, 2015 – Pulmonx Corporation, a leader in interventional pulmonology,...

Read more

REDWOOD CITY, Calif. – September 28, 2015 - Pulmonx®, a leader in interventional pulmonology, today announced the launch of a tablet version of its Chartis Pulmonary Assessment System, a diagnostic tool designed to identify optimal patients for Zephyr® Endobronchial Valve (EBV) therapy. The Chartis...

Read more

REDWOOD CITY, Calif. – July 1, 2015 –Pulmonx®, a leader in interventional pulmonology, today announced publication in The Lancet of results from the BeLieVeR-HIFi clinical trial, the first successful sham-controlled trial of any minimally invasive emphysema device. 

BeLieVeR-HIFi is a prospective,...

Read more

Denver, Colo. – May 18, 2015 – Pulmonx®, a leader in interventional pulmonology, today announced six month results from the independent, randomized, controlled STELVIO trial, which further validated the safety and efficacy of the Zephyr® Endobronchial Valve (EBV) in severe emphysema patients. The...

Read more

Denver, Colo. – May 18, 2015 –Pulmonx®, a leader in interventional pulmonology, today announced results from a retrospective analysis of the landmark VENT trial that demonstrated a statistically significant benefit in severe emphysema patients with homogeneous disease that received treatment with...

Read more
CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.
US / new visitor